Evaluation of patients with chronic obstructive pulmonary disease (COPD) and chronic kidney disease (CKD) who would benefit from aclidinium bromide treatment

Study identification

• EU PAS number:
  EUPAS4902
• Study ID:
  9109
• Official title and acronym:
  Evaluation of patients with chronic obstructive pulmonary disease (COPD) and chronic kidney disease (CKD) who would benefit from aclidinium bromide treatment
• DARWIN EU® study:
  No
• Study countries:
  United Kingdom
• Study description:
  A retrospective, observational study characterising patient groups already within the OPCRD with chronic obstructive pulmonary disease (COPD) and chronic kidney disease (CKD) who may benefit from initiation of long acting muscarinic antagonist (LAMA) therapy or a switch from tiotropium for safety reasons
• Study status:
  Finalised

Research institutions and networks

Institutions

Research in Real Life

Study timelines

Date when funding contract was signed

Planned: 17/09/2013

Actual: 17/09/2013

Study start date

Planned: 01/10/2013

Actual: 01/10/2013

Data analysis start date

Planned: 30/10/2013

Actual: 28/10/2013

Date of final study report

Planned: 31/12/2013

Actual: 30/12/2013

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Almirall

Regulatory

• Was the study required by a regulatory body?:
  No